Intraprostatic calcification and biochemical recurrence in men treated with cesium-131 prostate brachytherapy.

Abstract

PURPOSE:

Baseline intraprostatic calcification (IC) has been shown to be associated with a higher rate of biochemical recurrence (BCR) in men treated with iodine-125 prostate brachytherapy (PB). We evaluated this association in a cohort of men treated with cesium-131 PB.

METHODS AND MATERIALS:

We retrospectively reviewed the charts of all low- and intermediate-risk prostate cancer patients treated with cesium-131 PB +/- external beam radiotherapy (EBRT) at our institution from 2/2011 to 7/2018. Patients with < 24 months of follow up or those who received androgen deprivation therapy were excluded. Baseline IC status (defined as one or more ICs ≥ 5 mm) was determined on post-PB CT scans. Cox analysis was used to assess predictors of BCR and Kaplan-Meier survival curves were calculated.

RESULTS:

Two hundred and sixteen low- and intermediate-risk prostate cancer patients treated with cesium-131 PB +/- EBRT were included. Median follow up was 56.9 months (range 24.1-111.4). Overall, 76 (35.2%) patients had baseline IC and 140 (64.8%) did not. Baseline disease characteristics did not differ significantly between groups. On univariate Cox analysis, only risk group (p = 0.047) and initial PSA (p = 0.016) were significant predictors of BCR, whereas baseline IC was not (p = 0.11). The 5-year BCR-free survival in patients with versus without baseline IC was 97.7% versus 93.8% (p = 0.405), respectively.

CONCLUSIONS:

In a cohort of low- and intermediate-risk prostate cancer patients treated with cesium-131 PB, the rate of BCR in men with baseline IC was low and baseline IC was not associated with a higher risk of BCR.

• Authors: Michael D Schad, Joshua L Rodríguez-López, Ankur K Patel, Christopher J Houser, Zachary D Horne, Ronald M Benoit, Ryan P Smith, Sushil Beriwal
• Journal: Brachytherapy (Brachytherapy) 2021 Jul-Aug Vol. 20 Issue 4 Pg. 859-865 ISSN: 1873-1449 [Electronic] United States
• PMID: 33994343 (Publication Type: Journal Article, Research Support, N.I.H., Extramural)
• Copyright: Copyright © 2021 American Brachytherapy Society. Published by Elsevier Inc. All rights reserved.

Chemical References

• Androgen Antagonists
• Cesium Radioisotopes
• Cesium-131
• Prostate-Specific Antigen

Topics

• Androgen Antagonists
• Brachytherapy (methods)
• Cesium Radioisotopes
• Humans
• Male
• Prostate-Specific Antigen
• Prostatic Neoplasms (radiotherapy)
• Retrospective Studies